13th PharmaLab Congress

Analytics ▪ Bioanalytics ▪ Microbiology

Developments in Modern Pharmaceutical and Biopharmaceutical Laboratories

Düsseldorf/Neuss, Germany

24 - 26 November 2025



The Conferences

- NEW! Analytical Quality and Lifecycle Concepts
- GMP Compliance Trends in Analytical Laboratories
- Laboratory Optimization, Automation and Digitalization/Outsourcing in Pharmaceutical Laboratories
- NEW! Artificial Intelligence in Laboratories
- Cell and Gene Therapies/ ATMPs - Quality and Safety
- NEW! Bioanalytical Control of Biological Drug Substances and Products
- Bioassays/Potency Assays – Regulatory Requirements, Development and Routine Use
- Alternative and Rapid Microbiological Methods
- Endotoxin and Pyrogen Testing

Premium Sponsor 2025 charles river

CONCEPT HEIDELBERG
EUROPAS GRÖSSTE GMP/GDP AKADEMIE

Supported by ECA Academy Your GMP/GDP Information Source

Two Pre-Conference Workshops on 24 November 2025

6th International Mycoplasma qPCR Testing User Day

This Pre-Conference Workshop is directed to responsible personnel involved in Quality Control testing of biopharmaceuticals and biologics. It is also useful for service providers, such as contract research organisations and contract manufacturers.

Programme & Speakers:

Mycoplasma Testing – Authorities Point of View
Jan-Oliver Karo, Paul-Ehrlich Institut, German Federal Institute for Vaccines and Biomedicines

Nucleic Acid Testing for Mycoplasma Detection: From Regulatory Requirements to GMP Implementation
Dr Marc Meichenin, CleanCells
Dr Caroline Kassim Houssenaly, bioMérieux

Leveraging the Capabilities of qPCR in Rapid Mycoplasma Validation Study Design and Execution including a Case Study on Application in Investigation of a Contamination Event
Michael Brewer, Thermo Fisher Scientific

Guidelines for Choosing the Appropriate Mycoplasma Standards for Method Validation by NAT
Yoann Mainguy, Merck

Optimization and Implementation of the MycoSEQ SYBR and TaqMan Kits for Lot Release
Joleen Simpson, Lilly

Bridging Speed and Sensitivity: Validation of a Hybrid Mycoplasma Detection Method for Complex Product Matrices
Dr Lori Daane, Bionique Testing Laboratories

Summary, Q&A and Plenum Discussion
Alexander Bartes, Roche

Mycoplasma Platform for Rapid QC in Short-Shelf Life ATMPs
Dr Jonathan Hanley, Shimadzu

Quality Control of mRNA/LNP Products

This Pre-Conference is directed to responsible personnel involved in Quality Control testing of mRNA or LNP based products.

Programme & Speakers:

Microbiological Insights into the Analytical Life Cycle of mRNA-based Therapeutics
Dr Thomas Meindl, Labor LS

Addressing mRNA vaccines in the European Pharmacopoeia - New Ph. Eur. Texts
Dr Thuy Bourgeois, EDQM - Council of Europe

Building a Robust CMC Framework for mRNA Therapeutics: From Raw Materials to Drug Product Release
Dr Mohamad Toutounji, Molgenium

CMC Strategies for saRNA Therapeutics: Optimizing T7 Polymerase, IVT Processes, and Quality Control to Accelerate Clinical Translation
Mengqian Mao, Novoprotein

Setting up Specifications: Considerations and Approaches
Dr Jan M. Falcke, BioNTech

Homing In on Fit-for-Purpose Biophysical Techniques for mRNA and LNP Characterization
Dr Natalia Markova, Freelance Consultant

Endotoxin Detection via a Low-Cost Electrochemical Test Strip and Reader Approach
Prof Dr Damion Corrigan, Aureum DX

Case Studies for mRNA Therapeutics – Developing Reliable and Robust Potency Methods
Dr Frances Reichert, Eurofins

mRNA Products as ATMP and as Vaccine - Same Technology but Different Requirements
Dr Sabine Hauck, dequra pharma consult hauck

NEW TOPIC

Analytical Quality and Lifecycle Concepts

25 November 2025

Analytical Track

A Track Organised by the ECA Analytical Quality Control Group

ECA Analytical Quality Control Group
An ECA Foundation Interest Group

This conference track is intended for laboratory managers, supervisors and analysts, quality control managers, heads of quality control, qualified persons (QPs), analytical scientists, and senior laboratory staff.

Programme & Speakers:

KEYNOTE on 25 November 2025: Artificial Intelligence in Pharmaceutical Industries
Dr Marcel Franke, Senior Scientist Predictive Formulation, Process Solutions/Upstream & Process Materials R&D, Merck Life Science

Introduction to the Track and AQCG
Dr Christopher Burgess, Chairman ECA AQCG

The new AQCG Guideline on Sampling and Sample Management
Dr Christopher Burgess, Chairman ECA AQCG

Overview Instruments and Systems Lifecycle 'Fitness for Intended Use'
Dr Bob McDowall, R.D. McDowall Limited

Analytical Procedure Development Lifecycle 'Fitness for Intended Purpose'
Patrick Jackson, GSK

Performance Qualification of Analytical Procedures ICH Q2 (R2) & the revision of USP <1225>
Dr Gerd Jilge, Member of the ECA AQCG Board

Performance Qualification of Bioanalytical Procedures; Similarities and Differences
Margarita Sabater, Genmab

AQbD and its Impact on the Analytical Procedure Lifecycle
Dr Amanda Guiraldelli Mahr, RIC Group

Ongoing Procedure Performance Verification (New USP Draft General Information Chapter <1221>)
Dr Joachim Ermer, Ermer Quality Consulting

Good Documentation Practices and Data Integrity (USP <1229>)
Dr Christopher Burgess, Chairman ECA AQCG



Analytical Track

GMP Compliance Trends in Analytical Laboratories

26 November 2025

The aim of this conference is to address GMP compliance issues that are currently discussed as hot topics in analytical quality control laboratories and during GMP/ FDA inspections.

Programme & Speakers:

KEYNOTE on 26 November 2025: From Bog to Bedside: Lessons from the First Dedicated Phage Therapy Center in North America
Prof Dr Steffanie Strathdee, University of California San Diego School of Medicine/Co-Director at the Center for Innovative Phage Applications and Therapeutics

Set-up of a QC Laboratory as Part of Greenfield Facility
Ivana Heckel, ten23 health

Why every Factor matters in a Contamination Investigation
Jeanne Moldenhauer, Excellent Pharma Consulting, Inc.

Small CROs and Validation & Conduction of (Bio) Analytical Methods
Dr Timo G. Kretzschmar, TiKrESolution

Universal Study Design for Instrument Changes in Pharmaceutical Release Analytics
Dr Anne Ries, Boehringer Ingelheim Pharma

Auditing Audit Trails - QA vs QC Perspective
Martina Gjorgjevska, The FORCE CT
Apostol Todorovsk, Sinceritas

Audit Trail Requirements for Digitalised GMP Laboratories
Dr Bob McDowall, R.D. McDowall Limited

Evaluation of Stability Data: Extrapolation of Shelf-Life by Statistical Analysis
Dr Joachim Ermer, Ermer Quality Consulting

Improving Analytical Procedure Transfers in the Pharmaceutical Industry
Ulla Bondegaard, Novo Nordisk

Media Partners 2025:

European Biotechnology – Life Sciences and Industry Magazine
LABORWELT
transkript
LABORSCOPE
BioPharma Asia
rapid microbiology
GIT LABOR-FACHZEITSCHRIFT

All information and registration online at www.pharmalab-congress.com

Laboratory Optimization, Automation and Digitalization/ Outsourcing in Pharmaceutical Laboratories

25/26 November 2025

This conference provides practical tools and strategies to optimize laboratory processes, improve efficiency through automation and digitalization, and ensure GMP-compliant outsourcing of analytical activities. It is aimed at laboratory and quality control professionals as well as service providers in the pharmaceutical industry.

Programme & Speakers:

From Spreadsheets and Paper to Digital Alternatives: Navigating Compliance, Reducing Errors, and Embracing Smarter Systems
Carsten Jasper, Jasper Consulting

Implementation of a LIMS - Lessons Learned
Dr Xaver Schratt, GBA Pharma

Achieving Cost Excellence in GMP Labs – A Proven Maturity Model for Sustainable Results
Dr Johann Gregori, Author & Speaker

Beyond the Visible: Automating the Quest for Subvisible Particles in Parenteral Products by means of Microflow Imaging
Dr Melanie Zerulla-Wernitz, Vetter Pharma

From Traditional QC to Real-Time Volume Control: Enhancing Screening Data Quality
Tobias Brode, Liquimetrix

QC-Automation: Development of a Fully Automated Bioburden Testing Solution
Anke Hossfeld, Merck Life Science

The Role of AI and Automation in Environmental Monitoring (EM): Driving Standardization, Efficiency, and Innovation in Microbiology
Arnalda Giambra, Copan Group

From EM to Product Release: Transforming QC labs with connected EM Systems
Bernard Corcoran, Lonza

Accelerate Journey towards Pharma 4.0 with Next Gen Lab Solutions
Rajasekhar Gollapinni, Caliber

KEYNOTE on 25 November 2025: Artificial Intelligence in Pharmaceutical Industries
Dr Marcel Franke, Senior Scientist Predictive Formulation, Process Solutions/Upstream & Process Materials R&D, Merck Life Science

KEYNOTE on 26 November 2025: From Bog to Bedside: Lessons from the First Dedicated Phage Therapy Center in North America
Prof Dr Steffanie Strathdee, University of California San Diego School of Medicine/Co-Director at the Center for Innovative Phage Applications and Therapeutics

Practical Examples on Digitalization, Optimization & Simplification in QC-Labs
Dr Karl-Heinz Bauer, Training - Beratung - Coaching

From Instrument to Knowledge: How to Organize the Digitalization of your Laboratory?
Dr Steven van Helden, wega

Future Labs: Architecture, Automation and AI
Kambiz Hajizadeh-Zaker, Vollack GmbH & Co. KG
Christian Ziegler, BAT GmbH

Smart Organization in the Laboratory: 47% Time Savings with 100% Precision
Mario Schneider, Better Basics Laborbedarf

Standardization inside a Network of GMP Contract Laboratories
Dr Christoph Höppner, Eurofins BioPharma Product Testing Europe

The Art of Partnership: Managing Expectations in Pharma-CRO Relationships
Malin Molander, Svar Life Science

Microbial Qualification of Cleanrooms: Not only CFU counts - Big projects in different spotlights
Alexander Pfülb, Labor LS

Analytical Track

NEW TOPIC

Artificial Intelligence in Laboratories

25/26 November 2025

This conference aims to address the impact of Artificial Intelligence (AI) on pharmaceutical laboratories and explore AI applications in analytical processes, regulatory compliance, and quality control.

Programme & Speakers:

AI-History in a Nutshell
Dr Karl-Heinz Bauer, Training - Beratung - Coaching

AI needs Data Management and FAIR Data in the Lab
Christophe Girardey, wega

Accelerating Analytical Method Development with Predictive Modelling and AI
Dr Raquel Figueiredo, BIAL

Investigation and Root Cause Analysis using AI for Trending and Contamination Control
Susan Cleary, Novatek International

Responsible AI Development of Alternative Microbiological Methods used for Environmental Monitoring – a Case Study with the APAS Independence
Dr Steven Giglio, Clever Culture Systems

AI and GxPs: A Contradiction?
Dr Karl-Heinz Bauer, Training - Beratung - Coaching

Case Study: Machine learning for Mold vs Bacteria Identification
Lisa Mallam, bioMérieux

Case Study: AI-Based Automated Solution for Incubation and Colony Counting in Microbiological Quality Control
Camilla Giardini, Copan NewLab

KEYNOTE on 25 November 2025: Artificial Intelligence in Pharmaceutical Industries
Dr Marcel Franke, Senior Scientist Predictive Formulation, Process Solutions/Upstream & Process Materials R&D, Merck Life Science

KEYNOTE on 26 November 2025: From Bog to Bedside: Lessons from the First Dedicated Phage Therapy Center in North America
Prof Dr Steffanie Strathdee, University of California San Diego School of Medicine/Co-Director at the Center for Innovative Phage Applications and Therapeutics

Utilizing ChatGPT to Establish Company-Wide Harmonized Equipment and System Validation Standards
Isabella Küfner, Boehringer Ingelheim

Large Language Models in the Service of Quality: Analyzing the Quality of Documentation
Dr Colin Lischik, Boehringer Ingelheim

AI-powered Pharma: Transforming Drug Discovery, Development and Production
Siobhan Fleming, SIEMENS

Testimonials

Dr Sara Albarran, ABclonal Germany GmbH, Düsseldorf, Germany
„The PharmaLab Congress was an incredible opportunity to forge valuable connections and engage in insightful discussions, featuring exceptional speakers. I'm thrilled to have won the iPad and grateful for the experience!"

Marleen Hoozemans, MSD Biotech BV, Oss, The Netherlands
„I always enjoy visiting the stands during PharmaLab to see all the cool new technologies that are available each time. The event is a great way to connect with peers in the industry and to share and generate ideas. I also loved the photobooth to capture the good vibes that were going on at the event. I never thought I would win the lottery, although I always participate in the hope to win it one day! I was very delighted to be the winner of this year's lottery."

Cell and Gene Therapies/ATMP – Quality and Safety

25/26 November 2025

This conference focuses on microbiological and analytical quality requirements, suitable methods, and validation for manufacturers and developers of cells, tissues, cell- and tissue-based products, and ATMPs. Experts from authorities and industry will share insights on current regulations and practical implementation.

Programme & Speakers:

Update on ATMPs in the Ph. Eur.
Dr Solène Le Maux, EDQM

Understanding of Analytical Critical Quality Attributes (CQAs) for Viral Vector Characterization in Gene Therapy
Dr Maribel Navarro, Kymos

Strategy for Potency Determination of Gene Therapy Products
Dr Ulrike Herbrand, Charles River Laboratories

High-Throughput Single-Cell Potency Assays for Cell Therapy Development Using Droplet Microfluidics
Dr Stephanie van Loo, LiveDrop

Cell and Gene Therapy CQA Analysis using Mass Spectrometry
Daniel Waldera-Lupa, Protagene

Enhanced Precision and Robustness in CAR-T Manufacturing: A Comparative Study of qPCR and dPCR
Dr Daniela Rozkova, SCTBio

Validation of VCN Determination by dPCR on a Retroviral CAR-T Cell Product in Compliance with ICH Q14 and Q2(R2)
Katy Haussmann, Virchow Klinikum der Charité Berlin
Dr Daniel Lindemeier, Labor LS

Developing Control Strategies for an Off-the-Shelf Allogenic Cell Therapy Product: A Case Study
Dr Steven Braem, 3D-PharmXchange

Considerations of Viral Safety Strategies for Cell Therapies – A Suggested Approach for What to Include in Viral Safety Packages for Cell Therapies
Dr Kerstin Brack, Charles River Laboratories

KEYNOTE on 25 November 2025: Artificial Intelligence in Pharmaceutical Industries
Dr Marcel Franke, Senior Scientist Predictive Formulation, Process Solutions/Upstream & Process Materials R&D Merck Life Science

KEYNOTE on 26 November 2025: From Bog to Bedside: Lessons from the First Dedicated Phage Therapy Center in North America
Prof Dr Steffanie Strathdee, University of California San Diego School of Medicine/Co-Director at the Center for Innovative Phage Applications and Therapeutics

Avoiding Common Sterility Testing Compliance Gaps and Regulatory Observations During ATMP Sterility Testing
Marsha Steed, Steed MicroBio LLC

Enhancing Microbiological Quality Control with Ready-to-Use Microorganisms
Dr Megha Bajaj, bioMérieux

How to Build a Digitalized End-to-End Process for Environmental Monitoring for ATMPs Release
Johannes Oberdörfer, Rapid Micro Biosystems
Willem Dullaers, Lonza

The New Guideline on ATMPs and Further Regulatory Update on ATMPs
Dr Sabine Hauck, ECA ATMP Interest Group

NEW TOPIC

Bioanalytical Control of Biological Drug Substances and Products

25/26 November 2025

This conference offers insights into modern analytical methods for biological drug substances and products, with a focus on regulatory requirements and practical implementation. It is aimed at professionals involved in method selection, validation, and lifecycle management of laboratory methods.

Programme & Speakers:

The combined Analytical Identity Testing Strategy for Oligonucleotides (Nucleotides)
Dr Alexandra Heussner, Vetter Pharma

mRNA Analytics: Last Chance for Platform Methods? (Nucleotides)
Dr Jan M. Falcke, BioNTech

Platform Methods - RNA Integrity as Case Study
Susanne Ulrich, BioNTech

A Platform ddPCR Method for the Detection of Residual DNA in mRNA Samples (Nucleotides)
Dr Christian Schiller, Eurofins

Control of Process-Related Impurities (HCPs) and Regulatory Requirements (HCP/Regulatory)
Dr Erika Friedl, Paul-Ehrlich Institut, German Federal Institute for Vaccines and Biomedicines

Mass Spectrometry in risk-oriented Host Cell Protein Analysis: The Role and Integration of LC-MS/MS for Qualitative and Quantitative Risk Assessment of HCPs in Biopharmaceuticals (HCP)
Julia Rauch, Charles River Laboratories

The Role of Platform Host Cell Protein ELISAs in Biopharmaceutical Quality Control (HCP)
Dr Florian Semmelmann, Roche

Real Time Release Control Strategy for a Biotech Drug Product (Release)
Dr Susanne Gawenda, Roche

Implementation of a Cartridge-based CE-SDS/cIEF Instrument for Routine Measurement of Drug Product (Implementation)
Johannes Führer, VelaLabs/Tentamus
Clemens Graf, VelaLabs/Tentamus

KEYNOTE on 25 November 2025: Artificial Intelligence in Pharmaceutical Industries
Dr Marcel Franke, Senior Scientist Predictive Formulation, Process Solutions/Upstream & Process Materials R&D Merck Life Science

KEYNOTE on 26 November 2025: From Bog to Bedside: Lessons from the First Dedicated Phage Therapy Center in North America
Prof Dr Steffanie Strathdee, University of California San Diego School of Medicine/Co-Director at the Center for Innovative Phage Applications and Therapeutics

ICH Q5A – Prior Knowledge in Virus Testing and Clearance Studies
Dr Martin Spruth, AGES – Austrian Agency for Health and Food Safety

Pragmatic Implementation of ICH Q14: Capillary Electrophoresis for Virus Quantification (ICH Q14/Viruses)
Dr Ewoud van Tricht, Kantisto BV

Development of HPLC-based Methods for Separation and Subsequent Characterization of Morphological Subspecies of a VSV-based Therapeutic Virus
Dr Johannes Solzin, Boehringer Ingelheim

Mastering hcDNA: A Harmonized Approach for AAV Gene Therapies (Viruses/hcDNA)
Dr Denise Teber, Charles River Laboratories

Bioassays/Potency Assays – Regulatory Requirements, Development and Routine Use

25/26 November 2025

This conference offers Insights into the development, validation, and regulatory expectations for bioassays and potency assays across various biopharmaceutical modalities, including ATMPs and vaccines.

Programme & Speakers:

KEYNOTE on 25 November 2025: Artificial Intelligence in Pharmaceutical Industries
Dr Marcel Franke, Senior Scientist Predictive Formulation, Process Solutions/Upstream & Process Materials R&D Merck Life Science

KEYNOTE on 26 November 2025: From Bog to Bedside: Lessons from the First Dedicated Phage Therapy Center in North America
Prof Dr Steffanie Strathdee, University of California San Diego School of Medicine/Co-Director at the Center for Innovative Phage Applications and Therapeutics

Key Aspects of Assay Control throughout the Analytical Lifecycle
Dr Sonja Klingelhöfer, Richter Biologics

Reference Standard Qualifications and Re-Evaluations for Potency Assays
Dr Pieta Boon, MSD
Jos Weusten, MSD

Bioassay Primer: Model-Based Confidence Interval Effects
Dr Florian Müller-Sallanz, Stegmann Systems

Bioassay Relevant Texts in the Ph. Eur. as well as the Potency Strategy in the Ph. Eur. for mAbs
Dr Solène Le Maux, EDQM

A (Former) CDER Reviewer's Perspective on Potency Assays
Gerry Feldman, Formerly FDA

Challenges in Optimization and Validation of Potency Assays in a State Batch Testing Laboratory
Dr Lilija Miller, Paul-Ehrlich Institut, German Federal Institute for Vaccines and Biomedicines

Case Study: Validation and Bridging of a Flow Cytometry Potency Assay for a Therapeutic Monoclonal Antibody
Dr Frances Reichert, Eurofins

Of Mice and (Wo)Men - Development and Validation of a Cell-Based Bioassay for a Commercial Biopharmaceutical Offering an Ethical and Efficient Alternative to the Conventional In Vivo Mouse Assay
Simone Tomaschek, Roche

Case Study of an Enhanced Development for a Bioassay
Dr Simon Anderhub, Novartis

'Where Fat and Sugar Meet' - Setup of a Glucose Uptake Assay in Differentiated Adipocytes
Dr Ella Rosenzweig, VelaLabs

Advancing Bioassay Technologies with NanoBiT Split Luciferase
Dr Jamison Grailer, Promega

Combination of Cell-based Potency Assay with Digital Droplet PCR® Readout as Innovative and New Methodology for Characterization of RNAi Therapeutic Qfitlia®(Fitusiran)
Christine Graf, Sanofi

Development and Optimization of the Infectious Titer Assay (TCID50) for Recombinant AAV
Annemie Wielant, UCB

A Case Study on the Challenges of Establishing a Robust Cell-Based Bioassay for Plasmid DNA Potency Determination
Dr Thomas Danielsen, Novo Nordisk

Ensuring Consistency in Bioassay Method Transfer: Strategies for Overcoming Variability
Jessica Weaver, BioAgilytix

Making Cell-Based Potency Assays Work Better for QC: A Simpler, Stronger Solution
Peter Wolff, AGC Biologics

Optimizing Cell-Based Assays: A Case Study on Overcoming Development Challenges
Morgane Gesquière, UCB

Alternative and Rapid Microbiological Methods

25/26 November 2025

This conference will provide an opportunity to discuss the latest advances in technology as well as practical aspects and concerns for meeting regulatory requirements. State-of-the-art presentations by competent speakers from the authorities as well as industrial and academic experts will provide a comprehensive overview.

Programme & Speakers:

KEYNOTE on 25 November 2025: Artificial Intelligence in Pharmaceutical Industries
Dr Marcel Franke, Senior Scientist Predictive Formulation, Process Solutions/Upstream & Process Materials R&D, Merck Life Science

KEYNOTE on 26 November 2025: From Bog to Bedside: Lessons from the First Dedicated Phage Therapy Center in North America
Prof Dr Steffanie Strathdee, University of California San Diego School of Medicine/Co-Director at the Center for Innovative Phage Applications and Therapeutics

Update on RMM in the Ph. Eur.
Dr Thuy Bourgeois, EDQM

Vision AI in Microbiology QC: Robust Models Ensure Reliable Outcomes
Niek Van Overberghe, Microtechnix

Unlocking Microbial Strain Typing with Whole Genome Sequences
Dr Sujan Timilsina, Charles River Laboratories

Approach for Validation Microbial Identification Methods: Primary and Limited Validations
Marie-Laurence Baille, MSD

Development of Long Read Sequencing for Adventitious Virus Detection
Dr Dominik Meisohle, Boehringer Ingelheim

Next Generation digital PCR Technology for Sterility Testing of Cell and Gene Therapy Products
Dr Alexandra Müller-Scholz, Sartorius

Rapid, Phenotypic Sterility Testing for Cell and Gene Therapy Products: Validation of a Three-Day Protocol Using the calScreener+ Platform
Dr Wilhelm Paulander, Symcel

Moving the Needle for Sterility Testing: Towards a New, Rapid Sterility test to Allow Faster Release of CAR-T Drug Products
Dr Nore Struyf, Johnson & Johnson

Update/Additions to Performing Statistical Calculations for Quantitative Rapid Method Validation Criteria
Dr Michael Miller, Microbiology Consultants

Evaluation of an Automated Readout of APS
Simon Braun, Roche
Matthieu Giletti, Roche

Evaluation of RMBNucleus™ Mold Alarm Software Feature
Dr Yu-Wei Shieh, Boehringer Ingelheim

Automated Solid Phase Cytometry Applications: Bioburden Troubleshooting in Production and Sterility Testing Feasibility for mRNA Vaccines
Dr Thierry Bonnevay, Sanofi

Primary Validation of Rapid-C+, Advanced BFPC, for Real-Time Viable Particle Monitoring
Dr Svetlana Kiseleva, Plair

EM Plate Reading Using the APAS Independence
Juan González, Pfizer

Accelerating Release of Short Shelf-Life Therapies Through Automated Growth-Based Method Optimi-zation and Application of USP<72> "Safety Margin" Guidelines
Dr Caroline Kassim-Houssenaly, bioMérieux

Bridging ISO Standards and ARMM for Effective Air Monitoring
Corina Keller, MBV

Endotoxin and Pyrogen Testing – Pharmacopoeial and Scientific Developments

25/26 November 2025

This conference will inform you about current developments in Endotoxin and Pyrogen testing, implementation of new methods as well as the practical use of established test methods like LAL for Endotoxin testing.

Programme & Speakers:

Forty Years of Endotoxin Standardisation
Trusha Desai, National Institute for Biological Standards and Control, MHRA

Procedure for BET Sample Hold Time Discrepancies at Boehringer Ingelheim
Dr Gertrud Lallinger-Kube, Boehringer Ingelheim

Investigating Low Endotoxin Recovery (LER) and Pyrogenicity in Diverse Pharmaceutical Products
Dr Parysatis Sachs, Sanofi

Limit Test Validation – Balancing Business Risk and Patient Safety
Dr Anthea Darius, Microcoat
Claudia König, Sanofi

Advancements in Endotoxin Testing from the PSCI Report and Member Survey
Dr Shahjahan Shaid, GSK

Endotoxin Testing of Pharmaceutical Products using Synthetic Reagents
Poppy Cliffe, AstraZeneca

Product Validation with rCR at Bayer
Sandra Wieger, Bayer AG

Streamlined Validation of Recombinant Cascade Reagents: A Novel Approach Using Advanced Microfluidic Technology
Meg Provenzano, Veolia

Update on the Pyrogenicity in the Ph. Eur.
Dr Solène Le Maux, EDQM

RSE, CSE or Crude LPS Preparations? A Closer Look at Detection Variability
Luisa Burgmaier, Microcoat

MAT: Thoughts on Test Sensitivity, Pyrogen limits, MVD and Readout System
Dr Ingo Spreitzer, Paul-Ehrlich Institut, German Federal Institute for Vaccines and Biomedicines

KEYNOTE on 25 November 2025: Artificial Intelligence in Pharmaceutical Industries
Dr Marcel Franke, Senior Scientist Predictive Formulation, Process Solutions/Upstream & Process Materials R&D Merck Life Science

KEYNOTE on 26 November 2025: From Bog to Bedside: Lessons from the First Dedicated Phage Therapy Center in North America
Prof Dr Steffanie Strathdee, University of California San Diego School of Medicine/Co-Director at the Center for Innovative Phage Applications and Therapeutics

Shaping the Future of Pyrogen Testing: Regulatory Updates and the Role of MAT
Case Study: Qualification of a Reporter Gene-Based Monocyte Activation Test (MAT)
Dr Nicole Rieth
Dr Luca Benedan, Eurofins

Implementing A New Type of Monocyte Activation Test Method to Detect and Quantify Pyrogens in GMP Environment
Dr Katarzyna Marciniak-Darmochwal, Charles River Laboratories

MHRA – Results of Survey and Discussions/Podium Discussion
Dr Elliot Lilley, UK National Centre for the Replacement, Refinement & Reduction of animals in research

Next Generation MAT – Analytical Precision Meets Regulatory Confidence
Dr Eva Kritikou, MAT Research

Addressing the Major Flaw of Applying MAT Method 2 to Products with Low Endotoxin Recovery Effects, and Presenting a New Generation of Rapid, Simplified and Sensitive PBMC based MAT with FBS-free Medium
Dr Shabnam Solati, CTL-MAT LLC

HyPerMAT – Discover the Future of in Vitro Pyrogen Testing
Dr Johannes Lichti, HyQuality Dx

13th PharmaLab Congress

Analytics ▪ Bioanalytics ▪ Microbiology

PharmaLab: Key Points

Flexible Attendance

- Create your own individual conference programme
- Move freely between sessions and conference rooms
- One-day or two-day tickets available

Trade Exhibition on 25 & 26 November 2025

- Discover products & services in analytics, bioanalytics, microbiology
- Access to an accompanying exhibition (trade exhibition)

Networking Opportunities

- Social Event on the first evening on 25 November 2025
- Meet and exchange with delegates, speakers, exhibitors

Tickets & Fees

Early Bird Rebate until 31 August 2025

Save 100 € per Congress Day

~~€ 690,-~~ until 31.08.

One-Day Ticket: € ~~790,-~~ + VAT

- Access on 25 OR 26 November only

~~€ 1.380,-~~ until 31.08.

Two-Day Ticket: € ~~1.580,-~~ + VAT

- Access on both 25 & 26 November

Pre-Conference (24 November): € 690,- + VAT

- Can be combined with the congress

All tickets include lunch and beverages during the conferences and in breaks.

Scan the QR Code to go to registration page:

The location

Crowne Plaza Düsseldorf / Neuss
Rheinallee 1, 41460 Neuss
Phone: +49 (0) 2131 77 - 00
Fax: +49 (0) 2131 77 - 1367
E-mail: emailus@cphotelduesseldorfneuss.com
www.crowneplaza.com/neuss

The Trade Exhibition on 25 & 26 November 2025

Take the opportunity to visit the accompanying trade exhibition. More than 40 companies will be present. Have a look a them at

www.pharmalab-congress.com/exhibitor-infos.html

The Organiser

CONCEPT HEIDELBERG – On behalf of the ECA Academy
P.O. Box 10 17 64, D-69007 Heidelberg
Phone +49 (0) 6221/84 44 0
E-mail: info@concept-heidelberg.de
www.concept-heidelberg.com

For questions regarding Microbiology:
Axel H. Schroeder (Operations Director)
Phone: +49 (0) 6221/84 44 10
E-mail: schroeder@concept-heidelberg.de

For questions regarding Analytics:
Dr Markus Funk (Operations Director)
Phone: +49 (0) 6221/84 44 40,
E-mail: funk@concept-heidelberg.de

For questions regarding Bioanalytics:
Clemens Mundo (Operations Director)
Phone: +49 (0) 6221/84 44 42
E-mail: mundo@concept-heidelberg.de

For questions regarding reservation, hotel, organisation, exhibition etc.:
Ronny Strohwald (Organisation Manager)
Phone: +49 (0) 6221/84 44 51
E-mail: strohwald@concept-heidelberg.de

cf/24072025

All information and registration online at www.pharmalab-congress.com